Press Releases
May 17, 2022
Surface Oncology to Participate in Upcoming Investor Conferences
May 9, 2022
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2022
May 6, 2022
Surface Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 27, 2022
Surface Oncology to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual Meeting
April 21, 2022
Surface Oncology Named one of the 2022 Best Places to Work by Boston Business Journal
April 14, 2022
Surface Oncology Announces Initiation of Phase 2 Studies Evaluating SRF388 in Patients with Hepatocellular Carcinoma and Non-Small-Cell Lung Cancer
April 8, 2022
Surface Oncology Presents New SRF388 Data at the American Association for Cancer Research (AACR) Annual Meeting 2022
April 1, 2022
Surface Oncology Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
March 31, 2022
Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study
March 15, 2022
Surface Oncology Appoints Theresa Boni as General Counsel
Displaying 1 - 10 of 13